iBio (NYSEAMERICAN:IBIO) Shares Pass Above 50-Day Moving Average of $0.00

iBio, Inc. (NYSEAMERICAN:IBIO – Get Rating) crossed above its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $0.00 and traded as high as $0.95. iBio shares last traded at $0.93, with a volume of 87,659 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, JMP Securities cut iBio from an “outperform” rating to a “market perform” rating in a research report on Wednesday, February 15th.

iBio Trading Down 1.2 %

The company has a debt-to-equity ratio of 0.04, a current ratio of 1.38 and a quick ratio of 1.38.

iBio (NYSEAMERICAN:IBIO – Get Rating) last announced its earnings results on Tuesday, February 14th. The biotechnology company reported ($1.08) earnings per share (EPS) for the quarter. On average, sell-side analysts forecast that iBio, Inc. will post -4.37 earnings per share for the current year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the company. HighTower Advisors LLC acquired a new stake in shares of iBio during the first quarter worth $25,000. State Street Corp boosted its holdings in shares of iBio by 55.7% in the 1st quarter. State Street Corp now owns 48,059 shares of the biotechnology company’s stock valued at $100,000 after purchasing an additional 17,200 shares during the last quarter. US Bancorp DE boosted its holdings in shares of iBio by 178.4% in the 1st quarter. US Bancorp DE now owns 67,100 shares of the biotechnology company’s stock valued at $29,000 after purchasing an additional 43,000 shares during the last quarter. Dimensional Fund Advisors LP acquired a new position in shares of iBio in the 4th quarter valued at $33,000. Finally, Bank of New York Mellon Corp acquired a new position in shares of iBio in the 1st quarter valued at $183,000.

About iBio

(Get Rating)

iBio, Inc is a biotechnology company, which engages in the development and manufacture of biotherapeutics. It operates through the Biopharmaceuticals and Bioprocessing segments. The Biopharmaceuticals segment involves molecule discovery, development, and licensing activities. The Bioprocessing segment includes contract development and manufacturing services for recombinant proteins.